Breast Cancer

Preventing Paclitaxel-Related Infusion Reactions

March 24, 2021

Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.

Immunotherapy and ADCs Make Headway in Metastatic TNBC

March 22, 2021

Anthracyclines and taxanes remain a backbone in the early-stage setting of triple-negative breast cancer as further evaluations of immunotherapy in the neoadjuvant and adjuvant settings needs to be conducted—efforts that will continue to shape the treatment paradigm.

Study Explores Actionable Pathologic Variants in Caribbean Women With Breast or Ovarian Cancer

March 11, 2021

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

PARP Inhibitors Are a Mainstay in Metastatic Breast Cancer

March 08, 2021

Olaparib and talazoparib didn't show statistically significant improvements in overall survival compared with chemotherapy in certain patients with metastatic breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control.

Personalized Approach May Boost AI Adherence

January 06, 2021

Twice-weekly text message reminders did not improve adherence to aromatase inhibitors (AIs) for postmenopausal patients with early-stage breast cancer; therefore, increasing the odds of long-term adherence for this population will require more personalized approaches, explained Julie Gralow, MD.